Finding the Solution
CT-line is a comprehensive solution to solving the patient-recruitment problem. Recruiting enough qualified subjects who will go the length of a entire study is the golden ticket to ethical and meaningful research. We at CT-line are ready to ride the gauntlet with our sponsors. With the option of staged pricing models, you pay when your subjects meet milestones. With our unique patient acquisition and pre-screening technology, every subject we connect sponsors with is prepped and ready to enroll. In fact, we are so confident in our methods that sponsors don’t pay until subjects enroll. This is how we overcome lab and site burden for our sponsors and save them time and money.
There is more than just good advertising skills involved in recruiting the right patient for a trial. We understand that sponsors need diversity within the inclusion criteria to show generalizability and real-world efficacy. We have that covered too. With our proprietary targeting systems and demographic access, we ensure that trials meet and exceed all IRB and GCP inclusivity and diversity requirements. Have an extremely specific target? No problem, we use the same technology to laser focus in on the exact patients needed.
How We're Different
CT-Line engages potential subjects through education, communication, and a genuine desire to help people in need. We inform patients on how they might be able to overcome their adversities through participation and engagement. All of our communications with subjects are HIPAA compliant, secure, and follow strict ethical guidelines. We access patient pools through multiple different streams including social media, online search, video advertising , patient advocacy groups, support forums and many other venues.
Meet Our Team
Let's start with our founder Dr. Sushil Singla. Dr. Singla is a triple board-certified specialist in Physical Medicine and Rehabilitation and Spinal Cord Injury Medicine. He holds a diploma from both the American Board of Medical Specialties (ABMS) and the Royal College of Physicians and Surgeons of Canada (FRCPSC). During his training, he found himself dealing with the same issue that every major study deals with, subject recruitment. Despite having direct, unfettered access to patients himself, he struggled to meet study deadlines and recruitment goals. He knew that ground-breaking medical devices, therapies, and medications were being delayed and lives were being lost in the process. He couldn’t just sit around and watch.
He teamed up with his childhood friend Tyler Devin. Tyler Devin has been in the digital marketing space for 15 years. His company currently actively manages $2-$3MM a month in advertising spend and sends over 2.5 billion emails a year. This enables his team to generate hundreds of thousands of focused and high-quality leads in multiple verticals annually. Starting from his early days, he understood that marketing fundamentals were important but not enough to stand out and outperform. He set out to find some of the most creative minds and created digital systems that hone in on making lead generation and customer acquisition efficient and reproducible. His proprietary method was exactly the solution to Dr. Singla’s problem.
Along Tyler's journey, he met Peter Zhang. Peter spent the beginning of his career in finance. He started by launching many successful hedge funds like Flammarion Technology, 233 Asset Management, amongst others. Peter then transitioned into his advertising business where he has seen a lot of success. He has taken his finance and arbitrage trading experience into the internet data space. That is how he came across Tyler Devin. Tyler and him both brought a unique point of view to the advertising game and when they teamed up they were able to create cutting-edge innovative technology to help them dominate the marketing space.
From there, CT-Line took inception and now hosts a dedicated team of experts in both the digital world and the health and science industry.
Try our risk-free assessment.
With your protocol information, we’ll use real-world data to compile a complete and accurate assessment of how many qualified patients we can reach.